Design, synthesis and pharmacological evaluation of novel polycyclic heteroarene ethers as PDE10A inhibitors: Part II
作者:Sanjib Das、Dnyaneshwar E. Shelke、Rajendra L. Harde、Vijayshree B. Avhad、Neelima Khairatkar-Joshi、Srinivas Gullapalli、Praveen K. Gupta、Maulik N. Gandhi、Deepak K. Bhateja、Malini Bajpai、Ashwini A. Joshi、Megha Y. Marathe、Girish S. Gudi、Satyawan B. Jadhav、Mahamad Yunnus A. Mahat、Abraham Thomas
DOI:10.1016/j.bmcl.2014.06.028
日期:2014.8
We report the design and synthesis of novel pyrrolo[3,2-b]quinoline containing heteroarene ethers as PDE10A inhibitors with good to excellent potency, selectivity and metabolic stability. Further optimization of this primary series resulted in the identification of 1-methyl-3-(4-[3-(pyridine-4-yl)pyrazin-2-yl]oxy}phenyl)-1H-pyrrolo[3,2-b]pyridine 13a with good hPDE10A potency (IC50: 6.3 nM), excellent
我们报告设计和合成新型的吡咯并[3,2- b ]喹啉含有杂芳烃醚作为PDE10A抑制剂,具有优异的效能,选择性和代谢稳定性。该主要系列的进一步优化导致鉴定出1-甲基-3-(4-[3-(吡啶-4-基)吡嗪-2-基]氧基}苯基)-1 H-吡咯并[3,2 - b ]吡啶13A具有良好hPDE10A效力(IC 50:6.3 nM),对其他相关PDE的优异选择性和理想的理化性质。在啮齿动物中口服给药后,该化合物表现出较高的外周水平和足够的大脑水平。该化合物在与精神疾病,特别是精神分裂症有关的多种临床前动物模型中也显示出优异的功效。